Plancorp LLC raised its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 17.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,276 shares of the company’s stock after acquiring an additional 1,993 shares during the period. Plancorp LLC’s holdings in Eli Lilly and were worth $1,121,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. First Financial Bank Trust Division raised its stake in shares of Eli Lilly and by 11.3% in the 2nd quarter. First Financial Bank Trust Division now owns 5,705 shares of the company’s stock worth $469,000 after buying an additional 578 shares in the last quarter. Gateway Investment Advisers LLC raised its stake in shares of Eli Lilly and by 3.0% in the 2nd quarter. Gateway Investment Advisers LLC now owns 570,790 shares of the company’s stock worth $46,976,000 after buying an additional 16,549 shares in the last quarter. Pennsylvania Trust Co raised its stake in shares of Eli Lilly and by 78.7% in the 2nd quarter. Pennsylvania Trust Co now owns 14,020 shares of the company’s stock worth $1,154,000 after buying an additional 6,175 shares in the last quarter. Stokes & Hubbell Capital Management LLC bought a new stake in shares of Eli Lilly and in the 2nd quarter worth $300,000. Finally, Beutel Goodman & Co Ltd. raised its stake in shares of Eli Lilly and by 13.8% in the 2nd quarter. Beutel Goodman & Co Ltd. now owns 2,564,357 shares of the company’s stock worth $162,556,000 after buying an additional 311,417 shares in the last quarter. 76.35% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold 251,088 shares of company stock worth $22,041,236 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.
Shares of Eli Lilly and Co (LLY) traded down $0.33 during midday trading on Friday, hitting $85.49. The company had a trading volume of 5,813,870 shares, compared to its average volume of 3,320,000. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The firm has a market cap of $94,130.00, a PE ratio of 40.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.35. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm posted $0.88 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. sell-side analysts expect that Eli Lilly and Co will post 4.22 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.63%. Eli Lilly and’s payout ratio is currently 99.05%.
A number of analysts have recently commented on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 5th. Leerink Swann boosted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Goldman Sachs Group reissued a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Finally, Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $92.75.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/19/eli-lilly-and-co-lly-holdings-increased-by-plancorp-llc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.